Course Director

Matthew S. Johnson, MD, FSIR
Matthew S. Johnson, MD, FSIR

Indiana University School of Medicine
Indiana University Health
Indianapolis, Indiana


Richard S. Finn
Richard S. Finn, MD

David Geffen School of Medicine at UCLA
Los Angeles, California

Amit Singal
Amit Singal, MD, MS

UT Southwestern Medical Center
Dallas, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Description

Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC.

Target Audience

This activity has been designed to meet the educational needs of interventional radiologists, oncologists, and other clinicians involved in the management of patients with hepatocellular carcinoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Review pivotal clinical evidence on newly available systemic treatment options, including multikinase inhibitors, antiangiogenic agents, and checkpoint inhibitors, for newly diagnosed and previously treated patients with advanced HCC
  • Examine the potential role of combination systemic therapy approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy) for advanced HCC
  • Assess emerging evidence on novel multimodal approaches for intermediate- and advanced-stage HCC
  • Develop optimal multidisciplinary treatment plans based on available evidence, patient- and disease-related factors, and recommendations on timely transitions from locoregional to systemic options for patients with intermediate or advanced HCC

Providership, Credit, and Support

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Eisai, Inc., Genentech, and Merck & Co., Inc.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Matthew S. Johnson, MD, FSIR
Professor of Radiology and Surgery
Gary J. Becker Professor of Radiology Research
Director, Interventional Oncology
Director, Clinical Research, Department of Radiology
Indiana University School of Medicine
Indiana University Health

Matthew S. Johnson, MD, FSIR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Argon Medical; Boston Scientific; Bristol Myers Squibb; BTG; and Varian.
Grant/Research Support from ALN; Argon Medical; B. Braun Medical Inc.; Bard Pharmaceuticals; BTG; Cook; and Cordis. Contracted research goes to Institution or to the IVC Filter Study Foundation.
Stock Shareholder in Endoshape and FluidX.

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Bristol Myers Squibb; C stone; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche/Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Amit Singal, MD, MS
Associate Professor of Medicine
Medical Director of the Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Amit Singal, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer Corporation; Bristol Myers Squibb; Eisai Inc.; Exact Sciences; Exelixis, Inc.; F. Hoffmann-La Roche; Genentech, Inc.; Glycotest; GRAIL; Merck & Co., Inc.; Pharma Solutions; and Wako Diagnostics.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

William J. Wong, MD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from If you have questions regarding the receipt of your emailed certificate, please contact via email at

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.